|
US8053191B2
(en)
|
2006-08-31 |
2011-11-08 |
Westend Asset Clearinghouse Company, Llc |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
|
EP4039363A1
(en)
|
2010-11-12 |
2022-08-10 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
|
IL280133B2
(en)
|
2010-11-12 |
2023-04-01 |
Gen9 Inc |
Methods and devices for the synthesis of nucleic acids
|
|
US11560585B2
(en)
|
2011-01-31 |
2023-01-24 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
|
JP6069224B2
(ja)
|
2011-01-31 |
2017-02-01 |
アプライズ バイオ， インコーポレイテッド |
細胞において複数のエピトープを同定する方法
|
|
EA201391373A1
(ru)
|
2011-03-23 |
2014-07-30 |
Пайонир Хай-Бред Интернэшнл, Инк. |
Способы получения сложного локуса трансгенных признаков
|
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US20130059296A1
(en)
|
2011-08-26 |
2013-03-07 |
Gen9, Inc. |
Compositions and Methods For High Fidelity Assembly of Nucleic Acids
|
|
CA2850509C
(en)
|
2011-10-14 |
2023-08-01 |
President And Fellows Of Harvard College |
Sequencing by structure assembly
|
|
WO2014163886A1
(en)
|
2013-03-12 |
2014-10-09 |
President And Fellows Of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
|
CA2871505C
(en)
|
2012-04-24 |
2021-10-12 |
Gen9, Inc. |
Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
|
|
RU2645475C2
(ru)
|
2012-04-25 |
2018-02-21 |
Регенерон Фармасьютикалз, Инк. |
Опосредованное нуклеазой нацеливание с большими нацеливающими векторами
|
|
WO2013176772A1
(en)
|
2012-05-25 |
2013-11-28 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
WO2013192278A1
(en)
|
2012-06-19 |
2013-12-27 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
|
US20150191719A1
(en)
|
2012-06-25 |
2015-07-09 |
Gen9, Inc. |
Methods for Nucleic Acid Assembly and High Throughput Sequencing
|
|
KR101656236B1
(ko)
|
2012-10-23 |
2016-09-12 |
주식회사 툴젠 |
표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
|
|
ES2713243T3
(es)
|
2012-12-06 |
2019-05-20 |
Sigma Aldrich Co Llc |
Modificación y regulación del genoma basada en CRISPR
|
|
IL307735A
(en)
|
2012-12-12 |
2023-12-01 |
Broad Inst Inc |
Systems engineering, methods and optimal guiding components for sequence manipulation
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
PL2931898T3
(pl)
|
2012-12-12 |
2016-09-30 |
Le Cong |
Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
|
|
DK2921557T3
(en)
|
2012-12-12 |
2016-11-07 |
Broad Inst Inc |
Design of systems, methods and optimized sequence manipulation guide compositions
|
|
AU2013359199C1
(en)
|
2012-12-12 |
2021-06-17 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
EP4234696A3
(en)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
ES2701749T3
(es)
|
2012-12-12 |
2019-02-25 |
Broad Inst Inc |
Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP4481048A3
(en)
|
2012-12-17 |
2025-02-26 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
CN109913495B
(zh)
|
2013-02-20 |
2022-11-25 |
瑞泽恩制药公司 |
大鼠的遗传修饰
|
|
ES2901396T3
(es)
|
2013-03-14 |
2022-03-22 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
|
|
WO2014144155A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Regents Of The University Of Minnesota |
Engineering plant genomes using crispr/cas systems
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
|
AU2014228981B2
(en)
*
|
2013-03-15 |
2019-11-28 |
The General Hospital Corporation |
Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
SI2986729T1
(sl)
|
2013-04-16 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Ciljana sprememba genoma podgane
|
|
WO2014186585A2
(en)
*
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
US9873907B2
(en)
|
2013-05-29 |
2018-01-23 |
Agilent Technologies, Inc. |
Method for fragmenting genomic DNA using CAS9
|
|
KR102884236B1
(ko)
*
|
2013-06-04 |
2025-11-12 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Rna-가이드된 전사 조절
|
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
SG11201510284XA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
RU2716421C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
WO2015006498A2
(en)
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
CN105517579B
(zh)
*
|
2013-07-10 |
2019-11-15 |
哈佛大学校长及研究员协会 |
用于RNA向导的基因调节和编辑的正交Cas9蛋白
|
|
US20150044772A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US20160201072A1
(en)
|
2013-08-22 |
2016-07-14 |
Pioneer Hi-Bred International, Inc. |
Genome modification using guide polynucleotide/cas endonuclease systems and methods of use
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9925248B2
(en)
|
2013-08-29 |
2018-03-27 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for RNA-guided treatment of HIV infection
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
EP3988649B1
(en)
|
2013-09-18 |
2024-11-27 |
Kymab Limited |
Methods, cells and organisms
|
|
CA3194037A1
(en)
*
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
|
EP4372090A3
(en)
|
2013-11-07 |
2024-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
CN110951779B
(zh)
|
2013-12-11 |
2024-04-16 |
瑞泽恩制药公司 |
用于靶向修饰基因组的方法和组合物
|
|
ES2975317T3
(es)
|
2013-12-11 |
2024-07-04 |
Regeneron Pharma |
Métodos y composiciones para la modificación dirigida de un genoma
|
|
KR20250068794A
(ko)
|
2013-12-12 |
2025-05-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
|
AU2014362245A1
(en)
|
2013-12-12 |
2016-06-16 |
Massachusetts Institute Of Technology |
Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
|
|
KR20160097327A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
|
|
EP4219699A1
(en)
|
2013-12-12 |
2023-08-02 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080261B1
(en)
|
2013-12-12 |
2019-05-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
KR102209636B1
(ko)
|
2014-02-11 |
2021-01-29 |
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 |
Crispr 이용의 다중화된 게놈 조작
|
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
DK3116997T3
(da)
|
2014-03-10 |
2019-08-19 |
Editas Medicine Inc |
Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
|
EP3540061A1
(en)
|
2014-04-02 |
2019-09-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
EP3129490A4
(en)
|
2014-04-08 |
2017-10-04 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
|
MX2016014066A
(es)
|
2014-04-28 |
2017-05-03 |
Recombinetics Inc |
Edicion de genes multiples en cerdos.
|
|
JP2017518372A
(ja)
|
2014-05-30 |
2017-07-06 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
潜伏性ウイルス感染用の処置剤を送達するための組成物および方法
|
|
CN106795521B
(zh)
|
2014-06-06 |
2021-06-04 |
瑞泽恩制药公司 |
用于修饰所靶向基因座的方法和组合物
|
|
HUE049405T2
(hu)
|
2014-06-23 |
2020-09-28 |
Regeneron Pharma |
Nukleáz-közvetített DNS-összeállítás
|
|
RU2771532C2
(ru)
|
2014-06-26 |
2022-05-05 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленных генетических модификаций и способы их применения
|
|
WO2016007839A1
(en)
|
2014-07-11 |
2016-01-14 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
CA2954626A1
(en)
|
2014-07-11 |
2016-01-14 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
CA2954791C
(en)
*
|
2014-07-14 |
2025-11-18 |
The Regents Of The Univ Of California |
Crispr/cas transcriptional modulation
|
|
EP4079847A1
(en)
|
2014-07-30 |
2022-10-26 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016028843A2
(en)
|
2014-08-19 |
2016-02-25 |
President And Fellows Of Harvard College |
Rna-guided systems for probing and mapping of nucleic acids
|
|
NZ728437A
(en)
*
|
2014-08-27 |
2018-02-23 |
Caribou Biosciences Inc |
Methods for increasing cas9-mediated engineering efficiency
|
|
EP3633032A3
(en)
|
2014-08-28 |
2020-07-29 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
|
US20170298450A1
(en)
*
|
2014-09-10 |
2017-10-19 |
The Regents Of The University Of California |
Reconstruction of ancestral cells by enzymatic recording
|
|
BR112017003757A2
(pt)
|
2014-09-12 |
2017-12-26 |
Du Pont |
?plantas de milho, partes de planta de milho ou sementes de milho?
|
|
CN113930455A
(zh)
*
|
2014-10-09 |
2022-01-14 |
生命技术公司 |
Crispr寡核苷酸和基因剪辑
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
CA2963315A1
(en)
|
2014-10-15 |
2016-04-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
WO2016065364A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Life Technologies Corporation |
Compositions and methods for enhancing homologous recombination
|
|
AU2015335618B2
(en)
|
2014-10-24 |
2018-02-01 |
Avectas Limited |
Delivery across cell plasma membranes
|
|
US12180263B2
(en)
|
2014-11-06 |
2024-12-31 |
President And Fellows Of Harvard College |
Cells lacking B2M surface expression and methods for allogeneic administration of such cells
|
|
WO2016073990A2
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
BR112017010547A2
(pt)
|
2014-11-21 |
2018-02-27 |
Regeneron Pharma |
métodos para produção de uma modificação bialélica, modificação de um genoma dentro de uma célula, produção de uma geração f0 de um animal não humano e identificação de uma inserção de um inserto de ácido nucleico.
|
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
CN105695485B
(zh)
*
|
2014-11-27 |
2020-02-21 |
中国科学院上海生命科学研究院 |
一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用
|
|
KR102763527B1
(ko)
|
2014-12-03 |
2025-02-05 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
|
WO2016094679A1
(en)
|
2014-12-10 |
2016-06-16 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016100857A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
|
CA2971213C
(en)
|
2014-12-19 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
JP2017537645A
(ja)
*
|
2014-12-19 |
2017-12-21 |
アプライズ バイオ， インコーポレイテッド |
細胞の選択された部分集団中の複数エピトープを識別するための方法
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
US11248240B2
(en)
*
|
2015-01-29 |
2022-02-15 |
Meiogenix |
Method for inducing targeted meiotic recombinations
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
US11046952B2
(en)
*
|
2015-03-16 |
2021-06-29 |
The Broad Institute, Inc. |
Encoding of DNA vector identity via iterative hybridization detection of a barcode transcript
|
|
EP3553178A1
(en)
|
2015-03-27 |
2019-10-16 |
E. I. du Pont de Nemours and Company |
Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants
|
|
KR102648489B1
(ko)
|
2015-04-06 |
2024-03-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
KR102535217B1
(ko)
|
2015-04-24 |
2023-05-19 |
에디타스 메디신, 인코포레이티드 |
Ｃａｓ9 분자/가이드 ｒｎａ 분자 복합체의 평가
|
|
AU2016261600B2
(en)
|
2015-05-08 |
2021-09-23 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
JP7030522B2
(ja)
|
2015-05-11 |
2022-03-07 |
エディタス・メディシン、インコーポレイテッド |
幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
|
|
US11535871B2
(en)
*
|
2015-05-14 |
2022-12-27 |
University Of Southern California |
Optimized gene editing utilizing a recombinant endonuclease system
|
|
KR102451796B1
(ko)
|
2015-05-29 |
2022-10-06 |
노쓰 캐롤라이나 스테이트 유니버시티 |
크리스퍼 핵산을 사용하여 박테리아, 고세균, 조류 및 효모를 스크리닝하는 방법
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
GB2543873A
(en)
|
2015-05-29 |
2017-05-03 |
Agenovir Corp |
Compositions and methods for cell targeted HPV treatment
|
|
EP3919622A1
(en)
|
2015-06-01 |
2021-12-08 |
Temple University - Of The Commonwealth System of Higher Education |
Methods and compositions for rna-guided treatment of hiv infection
|
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
JP7396783B2
(ja)
|
2015-06-09 |
2023-12-12 |
エディタス・メディシン、インコーポレイテッド |
移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物
|
|
DK3307872T3
(da)
|
2015-06-15 |
2023-10-23 |
Univ North Carolina State |
Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober
|
|
MX392008B
(es)
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
CA2990699A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
|
WO2017011721A1
(en)
|
2015-07-15 |
2017-01-19 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
WO2017023801A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
|
CN108350062B
(zh)
|
2015-08-06 |
2022-10-14 |
达纳-法伯癌症研究所股份有限公司 |
靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
AU2016316845B2
(en)
|
2015-08-28 |
2022-03-10 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
EP3344771A4
(en)
*
|
2015-08-31 |
2019-03-20 |
Agilent Technologies, Inc. |
COMPOUNDS AND METHODS FOR CRISPR / CAS-BASED GENOME EDITATION THROUGH HOMOLOGOUS RECOMBINATION
|
|
US20180251789A1
(en)
*
|
2015-09-04 |
2018-09-06 |
Massachusetts Institute Of Technology |
Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
|
|
US11261439B2
(en)
|
2015-09-18 |
2022-03-01 |
President And Fellows Of Harvard College |
Methods of making guide RNA
|
|
WO2017053312A1
(en)
*
|
2015-09-21 |
2017-03-30 |
The Regents Of The University Of California |
Compositions and methods for target nucleic acid modification
|
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
|
US11286480B2
(en)
|
2015-09-28 |
2022-03-29 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
MX2018004263A
(es)
|
2015-10-08 |
2019-08-16 |
Harvard College |
Edición genómica multiplexada.
|
|
IL294014B2
(en)
|
2015-10-23 |
2024-07-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017074962A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Brandeis University |
Modified cas9 compositions and methods of use
|
|
GB2559526B
(en)
|
2015-11-03 |
2021-02-17 |
Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
|
AU2016353057C1
(en)
|
2015-11-11 |
2021-06-17 |
Regents Of The University Of Minnesota |
Biocontainment/biocontrol system and methods
|
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
EA201891317A3
(ru)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
|
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
|
AU2016380836A1
(en)
|
2015-12-30 |
2018-07-12 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
ES2875747T3
(es)
|
2016-01-11 |
2021-11-11 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia
|
|
BR112018013679A2
(pt)
|
2016-01-11 |
2019-01-22 |
Univ Leland Stanford Junior |
proteínas quiméricas e métodos de regulação de expressão gênica
|
|
CN105624187A
(zh)
*
|
2016-02-17 |
2016-06-01 |
天津大学 |
酿酒酵母基因组定点突变的方法
|
|
EP3417061B1
(en)
|
2016-02-18 |
2022-10-26 |
The Regents of the University of California |
Methods and compositions for gene editing in stem cells
|
|
WO2017151444A1
(en)
|
2016-02-29 |
2017-09-08 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
|
|
WO2017161043A1
(en)
|
2016-03-16 |
2017-09-21 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
US11421218B2
(en)
|
2016-03-23 |
2022-08-23 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
KR102670601B1
(ko)
|
2016-04-19 |
2024-05-29 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
CN109415761B
(zh)
|
2016-04-25 |
2022-09-20 |
哈佛学院董事及会员团体 |
用于原位分子检测的杂交链反应方法
|
|
JP2019514379A
(ja)
*
|
2016-04-28 |
2019-06-06 |
インダストリ−アカデミック コオペレーション ファウンデイション， ヨンセイ ユニヴァーシティＩｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ， Ｙｏｎｓｅｉ Ｕｎｉｖｅｒｓｉｔｙ |
Ｒｎａ誘導型ヌクレアーゼ活性のインビボ高スループット評価のための方法
|
|
IL262888B1
(en)
|
2016-05-20 |
2025-10-01 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide RNAs
|
|
WO2017205540A1
(en)
*
|
2016-05-24 |
2017-11-30 |
The Translational Genomics Research Institute |
Molecular tagging methods and sequencing libraries
|
|
BR112018074531B1
(pt)
|
2016-06-02 |
2021-01-19 |
Sigma-Aldrich Co. Llc |
composição que compreende um sistema de nuclease e seu uso, kit, método in vitro para aumentar a eficiência da modificação do genoma-alvo e método para detectar uma sequência cromossômica
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
DK3474669T3
(da)
|
2016-06-24 |
2022-06-27 |
Univ Colorado Regents |
Fremgangsmåde til generering af stregkodede kombinatoriske biblioteker
|
|
US12214056B2
(en)
|
2016-07-19 |
2025-02-04 |
Duke University |
Therapeutic applications of CPF1-based genome editing
|
|
WO2018022930A1
(en)
*
|
2016-07-27 |
2018-02-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immolative cell-penetrating complexes for nucleic acid delivery
|
|
CN109563505A
(zh)
|
2016-07-28 |
2019-04-02 |
帝斯曼知识产权资产管理有限公司 |
用于真核细胞的组装系统
|
|
EP3490373B1
(en)
|
2016-07-29 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
|
CA3032822A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CA3035534A1
(en)
*
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
|
WO2018064371A1
(en)
|
2016-09-30 |
2018-04-05 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
KR20240064734A
(ko)
|
2016-10-14 |
2024-05-13 |
더 제너럴 하스피탈 코포레이션 |
후성적으로 조절되는 부위-특이적 뉴클레아제
|
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
WO2018093797A1
(en)
|
2016-11-15 |
2018-05-24 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
|
CN110582302A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和/或蛋白有效负载递送的组合物和方法
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
CA3047904A1
(en)
|
2016-12-22 |
2018-06-28 |
Avectas Limited |
Vector-free intracellular delivery to non-adherent cells by reversible permeabilization
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
JP7219972B2
(ja)
|
2017-01-05 |
2023-02-09 |
ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー |
Ｄｎａ二本鎖切断に非依存的な標的化遺伝子編集プラットフォームおよびその用途
|
|
EP4095263A1
(en)
|
2017-01-06 |
2022-11-30 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
CN110446785B
(zh)
|
2017-01-23 |
2024-04-26 |
瑞泽恩制药公司 |
Hsd17b13变体及其应用
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
EP3580212A4
(en)
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
GB2575930A
(en)
|
2017-03-23 |
2020-01-29 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
|
US12331319B2
(en)
|
2017-04-12 |
2025-06-17 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
|
AU2018254547B2
(en)
|
2017-04-20 |
2024-06-13 |
Egenesis, Inc. |
Methods for generating genetically modified animals
|
|
AU2018254619B2
(en)
|
2017-04-21 |
2022-07-21 |
The General Hospital Corporation |
Variants of Cpf1 (CAS12a) with altered PAM specificity
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
|
US11834665B2
(en)
|
2017-05-10 |
2023-12-05 |
Regents Of The University Of Minnesota |
Programmable transcription factors and methods
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
US20200140842A1
(en)
|
2017-05-25 |
2020-05-07 |
The General Hospital Corporation |
Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
|
|
KR20200026874A
(ko)
|
2017-06-06 |
2020-03-11 |
지머젠 인코포레이티드 |
대장균 개량을 위한 htp 게놈 공학 플랫폼
|
|
CA3061984A1
(en)
|
2017-06-06 |
2018-12-13 |
Zymergen Inc. |
A htp genomic engineering platform for improving fungal strains
|
|
CN111065736A
(zh)
*
|
2017-06-07 |
2020-04-24 |
国立大学法人东京大学 |
针对颗粒状角膜变性症的基因治疗药物
|
|
AU2018279829B2
(en)
|
2017-06-09 |
2024-01-04 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
|
AU2018283405B2
(en)
|
2017-06-15 |
2025-06-26 |
The Regents Of The University Of California |
Targeted non-viral DNA insertions
|
|
EP3641811B1
(en)
|
2017-06-21 |
2025-02-26 |
ProKidney |
Immunoprivileged bioactive renal cells for the treatment of kidney disease
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
EP3585159B1
(en)
|
2017-07-31 |
2025-05-14 |
Regeneron Pharmaceuticals, Inc. |
Method of testing the ability of a crispr/cas9 nuclease to modify a target genomic locus in vivo, by making use of a cas-transgenic mouse or rat which comprises a cas9 expression cassette in its genome
|
|
US20190032156A1
(en)
|
2017-07-31 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
MX2020001177A
(es)
|
2017-07-31 |
2020-09-25 |
Regeneron Pharma |
Animales no humanos reporteros de crispr y usos de los mismos.
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CN111630177A
(zh)
|
2017-09-29 |
2020-09-04 |
英特利亚治疗股份有限公司 |
使用脂质纳米粒子的体外mrna递送方法
|
|
KR102822306B1
(ko)
|
2017-09-29 |
2025-06-19 |
인텔리아 테라퓨틱스, 인크. |
게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
|
|
AU2018338787C1
(en)
|
2017-09-29 |
2025-10-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for TTR gene editing and treating ATTR amyloidosis
|
|
CA3071712C
(en)
|
2017-09-29 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus and methods of use
|
|
EP3688162B1
(en)
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
USES OF BASIC EDITORS ADENOSINE
|
|
EP3700924A4
(en)
|
2017-10-27 |
2021-11-03 |
The Regents of the University of California |
TARGETED REPLACEMENT OF ENDOGENOUS T-CELL RECEPTORS
|
|
JP7416700B2
(ja)
|
2017-11-14 |
2024-01-17 |
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド |
増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
BR112020014168A2
(pt)
|
2018-01-12 |
2020-12-08 |
Basf Se |
Proteína, ácido nucleico isolado, gene recombinante, vetor, célula hospedeira, planta, parte de planta ou semente de trigo, métodos para produzir, produto de trigo, farinha, farelo integral, amido, grânulos de amido ou farelo de trigo e métodos para identificar e/ou selecionar uma planta de trigo
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
US20220010293A1
(en)
|
2018-02-23 |
2022-01-13 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
EP3765614A1
(en)
|
2018-03-14 |
2021-01-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
AU2019239880B2
(en)
|
2018-03-19 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using CRISPR/Cas systems
|
|
KR20210003819A
(ko)
|
2018-04-19 |
2021-01-12 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
유전자 편집을 위한 조성물 및 방법
|
|
KR102852347B1
(ko)
|
2018-05-11 |
2025-09-01 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
|
|
EP3794130A4
(en)
|
2018-05-16 |
2022-07-27 |
Synthego Corporation |
METHODS AND SYSTEMS FOR DESIGNING AND USING GUIDE RNA
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
CN112513243A
(zh)
|
2018-06-01 |
2021-03-16 |
阿维塔斯有限公司 |
细胞工程平台
|
|
AU2019291918B2
(en)
|
2018-06-29 |
2025-06-12 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
CN112513270B
(zh)
|
2018-07-13 |
2025-02-25 |
加利福尼亚大学董事会 |
基于逆转录转座子的递送媒介物及其使用方法
|
|
BR112021001546A2
(pt)
|
2018-07-31 |
2021-05-04 |
Intellia Therapeutics, Inc. |
composições e métodos para a edição de gene do hidroxiácido oxidase 1 (hao1) para o tratamento da hiperoxalúria primária tipo 1 (ph1)
|
|
SG11202102068TA
(en)
|
2018-07-31 |
2021-03-30 |
Broad Inst Inc |
Novel crispr enzymes and systems
|
|
CN110678553B
(zh)
*
|
2018-08-21 |
2023-08-11 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
在哺乳动物干细胞中进行基因组编辑的方法
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
TW202028460A
(zh)
|
2018-09-28 |
2020-08-01 |
美商英特利亞醫療公司 |
用於乳酸脫氫酶(ldha)基因編輯之組合物及方法
|
|
US10711267B2
(en)
|
2018-10-01 |
2020-07-14 |
North Carolina State University |
Recombinant type I CRISPR-Cas system
|
|
US12264330B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
|
|
US12264313B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
|
|
US12203123B2
(en)
|
2018-10-01 |
2025-01-21 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
SG11202103571XA
(en)
|
2018-10-16 |
2021-05-28 |
Intellia Therapeutics Inc |
Compositions and methods for immunotherapy
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
EP3874037A4
(en)
|
2018-10-31 |
2021-12-15 |
Zymergen, Inc. |
DETERMINIST MULTIPLEXED SET OF DNA LIBRARIES
|
|
EP3874048A1
(en)
*
|
2018-11-01 |
2021-09-08 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US12460189B2
(en)
|
2018-11-09 |
2025-11-04 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
CN113166744B
(zh)
|
2018-12-14 |
2025-02-07 |
先锋国际良种公司 |
用于基因组编辑的新颖crispr-cas系统
|
|
SG11202105189RA
(en)
|
2018-12-20 |
2021-06-29 |
Regeneron Pharma |
Nuclease-mediated repeat expansion
|
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
US12460230B2
(en)
|
2019-02-10 |
2025-11-04 |
The J. David Gladstone Institutes |
Modified mitochondrion and methods of use thereof
|
|
EP3935156A4
(en)
|
2019-03-07 |
2022-12-28 |
The Regents of The University of California |
CRISPR-CAS EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
|
KR20210136997A
(ko)
|
2019-03-08 |
2021-11-17 |
지머젠 인코포레이티드 |
미생물에서 반복적 게놈 편집
|
|
IL312893A
(en)
|
2019-03-18 |
2024-07-01 |
Regeneron Pharma |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
|
KR102683424B1
(ko)
|
2019-03-18 |
2024-07-10 |
리제너론 파마슈티칼스 인코포레이티드 |
타우 응집과 관련된 유전적 취약성을 식별하기 위한 CRISPR/Cas 드랍아웃 스크리닝 플랫폼
|
|
DE112020001342T5
(de)
|
2019-03-19 |
2022-01-13 |
President and Fellows of Harvard College |
Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
|
|
SG11202110434PA
(en)
|
2019-03-28 |
2021-10-28 |
Intellia Therapeutics Inc |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
KR20220004649A
(ko)
|
2019-03-28 |
2022-01-11 |
인텔리아 테라퓨틱스, 인크. |
폴리펩티드 발현을 위한 폴리뉴클레오티드, 조성물 및 방법
|
|
KR20220004984A
(ko)
|
2019-03-28 |
2022-01-12 |
인텔리아 테라퓨틱스, 인크. |
Ttr 유전자 편집을 위한 조성물 및 방법 및 코르티코스테로이드를 포함하는 attr 아밀로이드증의 치료 또는 그의 용도
|
|
EP3945800A1
(en)
|
2019-04-03 |
2022-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
|
CN117178959A
(zh)
|
2019-04-04 |
2023-12-08 |
瑞泽恩制药公司 |
包括人源化凝血因子12基因座的非人动物
|
|
SG11202108524SA
(en)
|
2019-04-04 |
2021-09-29 |
Regeneron Pharma |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP7610339B2
(ja)
|
2019-06-04 |
2025-01-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
|
|
BR112021022722A2
(pt)
|
2019-06-07 |
2022-01-04 |
Regeneron Pharma |
Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
|
|
EP3813522B1
(en)
|
2019-06-14 |
2025-05-07 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
|
CA3152288A1
(en)
|
2019-08-27 |
2021-03-04 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
|
CN114616002A
(zh)
|
2019-09-13 |
2022-06-10 |
瑞泽恩制药公司 |
使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
|
|
CN115175996A
(zh)
|
2019-09-20 |
2022-10-11 |
博德研究所 |
新颖vi型crispr酶和系统
|
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
|
BR112022008468A2
(pt)
*
|
2019-11-01 |
2022-07-19 |
Shanghai Bluecross Medical Science Inst |
Método para modificação direcionada de uma sequência de genoma de planta
|
|
IL292605B2
(en)
|
2019-11-08 |
2025-09-01 |
Regeneron Pharma |
CRISPR and AAV strategies for treating childhood X-linked retinoschisis
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
CN114945273B
(zh)
|
2019-11-29 |
2025-08-12 |
巴斯夫欧洲公司 |
增加植物对抗真菌感染的抗性
|
|
CN115485387A
(zh)
|
2019-12-19 |
2022-12-16 |
巴斯夫欧洲公司 |
增加精细化学品生产中的时空产率、碳转化效率和碳底物灵活性
|
|
CN115135762A
(zh)
|
2019-12-20 |
2022-09-30 |
巴斯夫欧洲公司 |
降低萜烯的毒性和增加微生物的生产潜力
|
|
US11060141B1
(en)
|
2019-12-23 |
2021-07-13 |
Stilla Technologies |
Multiplex drop-off digital polymerase chain reaction methods
|
|
IL295280A
(en)
|
2020-02-07 |
2022-10-01 |
Intellia Therapeutics Inc |
Preparations and methods for editing the kallikrein gene (klkb1)
|
|
CA3167369A1
(en)
|
2020-03-04 |
2021-09-10 |
Tara YOUNG |
Methods and compositions for sensitization of tumor cells to immune therapy
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
US20210290757A1
(en)
|
2020-03-23 |
2021-09-23 |
Avectas Limited |
Engineering of dendritic cells for generation of vaccines against sars-cov-2
|
|
US12057197B2
(en)
|
2020-04-03 |
2024-08-06 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
|
WO2021204877A2
(en)
|
2020-04-08 |
2021-10-14 |
Astrazeneca Ab |
Compositions and methods for improved site-specific modification
|
|
JP2023524666A
(ja)
|
2020-04-28 |
2023-06-13 |
インテリア セラピューティクス，インコーポレイテッド |
インビトロ細胞送達の方法
|
|
GB2614813B
(en)
|
2020-05-08 |
2025-05-07 |
Harvard College |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
WO2022008935A1
(en)
|
2020-07-10 |
2022-01-13 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
US20220096606A1
(en)
|
2020-09-09 |
2022-03-31 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
|
|
EP4222167A1
(en)
|
2020-09-30 |
2023-08-09 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
|
CA3196116A1
(en)
|
2020-10-21 |
2022-04-28 |
Omar Abudayyeh |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
|
WO2022098933A1
(en)
|
2020-11-06 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
|
US20240002839A1
(en)
|
2020-12-02 |
2024-01-04 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
WO2022125982A1
(en)
|
2020-12-11 |
2022-06-16 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class ii in a cell
|
|
CR20230321A
(es)
|
2020-12-23 |
2023-09-12 |
Intellia Therapeutics Inc |
Composiciones y métodos para modificar genéticamente ciita en una célula
|
|
TW202239959A
(zh)
|
2020-12-23 |
2022-10-16 |
美商英特利亞醫療公司 |
用於減少細胞中hla-a之組合物及方法
|
|
US20240067954A1
(en)
|
2021-01-05 |
2024-02-29 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
AU2022213019A1
(en)
|
2021-02-01 |
2023-08-10 |
Avectas Limited |
Delivery platform
|
|
EP4288089A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
|
CN117098840A
(zh)
|
2021-02-08 |
2023-11-21 |
因特利亚治疗公司 |
用于免疫疗法的自然杀伤细胞受体2b4组合物和方法
|
|
WO2022170194A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
|
WO2022182957A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
|
TW202246510A
(zh)
|
2021-02-26 |
2022-12-01 |
美商維泰克斯製藥公司 |
以crispr/slucas9治療第1型肌強直性營養不良之組合物及方法
|
|
US20240182890A1
(en)
|
2021-04-07 |
2024-06-06 |
Astrazeneca Ab |
Compositions and methods for site-specific modification
|
|
EP4320235A1
(en)
*
|
2021-04-07 |
2024-02-14 |
Century Therapeutics, Inc. |
Gene transfer vectors and methods of engineering cells
|
|
WO2022221695A1
(en)
|
2021-04-17 |
2022-10-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
CN117940426A
(zh)
|
2021-04-17 |
2024-04-26 |
英特利亚治疗股份有限公司 |
Dna依赖性蛋白质激酶抑制剂以及其组合物和用途
|
|
TW202308597A
(zh)
|
2021-04-17 |
2023-03-01 |
美商英特利亞醫療公司 |
脂質奈米顆粒組合物
|
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
|
WO2022240846A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
JP2024520676A
(ja)
|
2021-06-02 |
2024-05-24 |
ライエル・イミュノファーマ・インコーポレイテッド |
Ｎｒ４ａ３欠損免疫細胞及びその使用
|
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
|
WO2023028471A1
(en)
|
2021-08-24 |
2023-03-02 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
|
KR20240055811A
(ko)
|
2021-09-10 |
2024-04-29 |
애질런트 테크놀로지스, 인크. |
프라임 편집을 위한 화학적 변형을 갖는 가이드 rna
|
|
EP4408996A2
(en)
|
2021-09-30 |
2024-08-07 |
Astrazeneca AB |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
KR20240082391A
(ko)
|
2021-10-14 |
2024-06-10 |
론자 세일즈 아게 |
세포외 소포 생산을 위한 변형된 생산자 세포
|
|
CR20240195A
(es)
|
2021-10-14 |
2024-06-20 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnhc coexpresados y sistemas de compuerta lógica
|
|
CN118251491A
(zh)
|
2021-10-28 |
2024-06-25 |
瑞泽恩制药公司 |
用于敲除C5的CRISPR/Cas相关方法及组合物
|
|
KR20240099393A
(ko)
|
2021-11-01 |
2024-06-28 |
톰 바이오사이언시스, 인코포레이티드 |
유전자 편집 기구와 핵산 카고의 동시 전달을 위한 단일 작제물 플랫폼
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
EP4426338A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
MX2024005242A
(es)
|
2021-11-03 |
2024-07-02 |
Intellia Therapeutics Inc |
Polinucleotidos, composiciones y metodos para la edicion del genoma.
|
|
EP4444089A1
(en)
|
2021-12-08 |
2024-10-16 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
IL313765A
(en)
|
2021-12-22 |
2024-08-01 |
Tome Biosciences Inc |
Joint provision of a gene editor structure and a donor template
|
|
CN119325508A
(zh)
|
2021-12-29 |
2025-01-17 |
百时美施贵宝公司 |
着陆垫细胞系的生成
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
EP4473103A2
(en)
|
2022-02-02 |
2024-12-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
EP4490291A1
(en)
|
2022-03-08 |
2025-01-15 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
US20250332287A1
(en)
|
2022-04-29 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
CN119947735A
(zh)
|
2022-05-19 |
2025-05-06 |
莱尔免疫制药公司 |
靶向nr4a3的多核苷酸及其用途
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
JP2025521154A
(ja)
|
2022-05-31 |
2025-07-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃ９ｏｒｆ７２反復伸長疾患のためのｃｒｉｓｐｒ干渉療法
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
CA3262406A1
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Man Inc |
Gene editing components, systems and methods of use
|
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
CA3261203A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharma |
COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
|
|
EP4565603A1
(en)
|
2022-08-05 |
2025-06-11 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
|
EP4593872A1
(en)
|
2022-09-28 |
2025-08-06 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
JP2025537750A
(ja)
|
2022-11-10 |
2025-11-20 |
セイル バイオメディシンズ インコーポレイテッド |
脂質ナノ粒子または脂質再構成天然メッセンジャーパックを含むｒｎａ組成物
|
|
CN120500498A
(zh)
|
2022-11-14 |
2025-08-15 |
瑞泽恩制药公司 |
用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法
|
|
KR20250124819A
(ko)
|
2022-12-21 |
2025-08-20 |
인텔리아 테라퓨틱스, 인크. |
프로단백질 전환효소 서브틸리신 켁신 9(pcsk9) 편집을 위한 조성물 및 방법
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
CN120936364A
(zh)
|
2023-01-27 |
2025-11-11 |
瑞泽恩制药公司 |
修饰的弹状病毒糖蛋白及其用途
|
|
TW202436622A
(zh)
|
2023-03-06 |
2024-09-16 |
美商英特利亞醫療公司 |
用於ｂ型肝炎病毒（ｈｂｖ）基因體編輯之組合物及方法
|
|
WO2024186971A1
(en)
|
2023-03-07 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Cish compositions and methods for immunotherapy
|
|
WO2024201368A1
(en)
|
2023-03-29 |
2024-10-03 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024243031A2
(en)
|
2023-05-19 |
2024-11-28 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
WO2024259309A1
(en)
|
2023-06-15 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Gene therapy for hearing disorders
|
|
WO2025006963A1
(en)
|
2023-06-30 |
2025-01-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
WO2025029662A1
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
TW202513801A
(zh)
|
2023-07-28 |
2025-04-01 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
|
|
WO2025029654A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
WO2025027165A1
(en)
|
2023-08-01 |
2025-02-06 |
Basf Plant Science Company Gmbh |
Increased resistance by expression of an ics protein
|
|
WO2025027166A1
(en)
|
2023-08-01 |
2025-02-06 |
Basf Plant Science Company Gmbh |
Increased resistance by expression of msbp1 protein
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
TW202515994A
(zh)
|
2023-08-14 |
2025-04-16 |
美商英特利亞醫療公司 |
用於對ｃｄ７０進行基因修飾之組合物及方法
|
|
TW202515992A
(zh)
|
2023-08-14 |
2025-04-16 |
美商英特利亞醫療公司 |
用於對轉形生長因子β受體２型（ＴＧＦβＲ２）進行基因修飾之組合物及方法
|
|
TW202521564A
(zh)
|
2023-08-14 |
2025-06-01 |
美商英特利亞醫療公司 |
用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025078978A1
(en)
|
2023-10-09 |
2025-04-17 |
Avectas Limited |
Transfection of cells via reversible permeabilization
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025111340A1
(en)
*
|
2023-11-20 |
2025-05-30 |
William Marsh Rice University |
Engineered extrachromosomal nucleic acids and methods of use thereof
|
|
WO2025149983A2
(en)
|
2024-01-12 |
2025-07-17 |
Avectas Limited |
Delivery platform with integrated non-viral transfection and cell processing
|
|
WO2025149984A2
(en)
|
2024-01-12 |
2025-07-17 |
Avectas Limited |
Delivery platform with flow-through system (fts)
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025162985A1
(en)
|
2024-01-30 |
2025-08-07 |
Basf Plant Science Company Gmbh |
Increased plant disease resistance by expression of a glycine-rich protein
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025202473A1
(en)
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
WO2025217398A1
(en)
|
2024-04-10 |
2025-10-16 |
Lyell Immunopharma, Inc. |
Methods for culturing cells with improved culture medium
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|